22:28 , Aug 27, 2018 |  BC Extra  |  Clinical News

Pfizer eyes submission after TTR readout; Alnylam gets bump

Pfizer Inc. (NYSE:PFE) reported detailed data from the Phase III ATTR-ACT trial of tafamidis meglumine in patients with transthyretin (TTR) cardiomyopathy showing that the drug led to a 30% improvement in all-cause mortality. However, investors...
20:52 , Apr 5, 2018 |  BC Week In Review  |  Clinical News

Alnylam reports Phase I data for subcutaneous RNAi therapeutic

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) reported top-line data from a single-blind, U.K. Phase I trial in 80 healthy volunteers showing that single ascending doses of 5-300 mg subcutaneous ALN-TTRsc02 led to "robust" knockdown of transthyretin (TTR)...
18:09 , Mar 16, 2018 |  BC Week In Review  |  Company News

Sanofi declines option for Alnylam's lumasiran

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) said the Genzyme Corp. unit of Sanofi (Euronext:SAN; NYSE:SNY) declined to exercise its exclusive option to obtain development and commercialization rights to lumasiran (ALN-GO1) outside the U.S., Canada and Western Europe....
21:11 , Mar 12, 2018 |  BC Extra  |  Company News

Sanofi declines option for Alnylam's lumasiran

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) said the Genzyme Corp. unit of Sanofi (Euronext:SAN; NYSE:SNY) declined to exercise its exclusive option to obtain development and commercialization rights to lumasiran (ALN-GO1) outside the U.S., Canada and Western Europe....
01:27 , Jan 13, 2018 |  BioCentury  |  Strategy

Remapping growth

As patisiran and fitusiran get closer to market, Alnylam Pharmaceuticals Inc. and Sanofi Genzyme concluded that the territorial complexity of their partnership for the products would limit their commercial value. Amendments announced on Jan. 7...
18:25 , Jan 12, 2018 |  BC Week In Review  |  Company News

Sanofi, Alnylam restructure RNAi therapeutics deal

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) gained global development and commercialization rights to transthyretin (TTR)-mediated amyloidosis candidates patisiran (ALN-TTR02) and ALN-TTRsc02 after it and Sanofi (Euronext:SAN; NYSE:SNY) amended their 2012 deal. The pharma and its Sanofi Genzyme...
01:08 , Jan 9, 2018 |  BC Extra  |  Company News

Alnylam, Sanofi restructure RNAi therapeutics deal

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) gained global development and commercialization rights to transthyretin (TTR)-mediated amyloidosis candidates patisiran (ALN-TTR02) and ALN-TTRsc02 after it and Sanofi (Euronext:SAN; NYSE:SNY) amended their 2012 deal. The pharma and its Sanofi Genzyme...
07:00 , Oct 10, 2016 |  BioCentury  |  Finance

Program or platform?

The slashing of $3.6 billion from Alnylam Pharmaceuticals Inc .'s market cap in a little more than a week suggests the markets are not comfortable with the company's argument that problems from two dropped programs...
07:00 , Jun 20, 2016 |  BC Week In Review  |  Clinical News

ALN-TTRsc02: Phase I started

Alnylam began a single-blind, placebo-controlled, U.K. Phase I trial to evaluate single ascending doses of subcutaneous ALN-TTRsc02 in up to 100 healthy volunteers. The Genzyme Corp. unit of Sanofi (Euronext:SAN; NYSE:SNY, Paris, France) has an...
07:00 , Oct 19, 2015 |  BC Week In Review  |  Clinical News

Alnylam preclinical data

In non-human primates, a single dose of 1 mg/kg subcutaneous ALN-TTRsc02 led to TTR knockdown of up to 99% with sustained knockdown of >50% for >84 days. Once-monthly 1 mg/kg ALN-TTRsc02 led to sustained TTR...